Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065075 · ClinicalTrials.gov registry record · Phase 3
Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
A Phase 3 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT03065075: Completed Phase 3 study, sponsored by University of Massachusetts, Worcester.
NCT03065075 is a Phase 3 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 152 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03065075, a Phase 3 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.
Primary Outcome
Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.
Interventions
- DRUG Phenazopyridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2019-02-28 |
| Phase | Phase 3 |
What the finished NCT03065075 record still lists
NCT03065075 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Phenazopyridine is the first listed.
NCT03065075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03065075 about?
NCT03065075 is a clinical study titled "Effect of Phenazopyridine on Prolapse Surgery Voiding Trials". To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.
What is the current status of trial NCT03065075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2017-02-01. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT03065075?
The interventions under investigation include: Phenazopyridine (DRUG).
Who is sponsoring clinical trial NCT03065075?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03065075's enrollment target sits among peer trials
152 1513th of 2000 higher than 484 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI